Thapa, BibechanPathak, Samyam BickramJha, NishaSijapati, Milesh JungShankar, Pathiyil Ravi2025-12-122025-12-122022https://hdl.handle.net/20.500.14572/3592Bibechan Thapa Department of Emergency Medicine, Kirtipur Hospital, Kirtipur, Kathmandu, Nepal Samyam Bickram Pathak Department of Intensive Care Unit, Nepal Mediciti Hospital, Bhaisepati, Lalitpur, Nepal https://orcid.org/0000-0001-9085-3135 Nisha Jha Department of Clinical Pharmacology, KIST Medical College and Teaching Hospital, Mahalaxmi, Lalitpur, Nepal https://orcid.org/0000-0003-1089-6042 Milesh Jung Sijapati Department of Internal Medicine, KIST Medical College and Teaching Hospital, Mahalaxmi, Lalitpur, Nepal https://orcid.org/0000-0001-6797-4764 Pathiyil Ravi Shankar IMU Center for Education, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia https://orcid.org/0000-0001-6105-5636Abstract Introduction: Antimicrobial resistance is a global health problem. The widespread and improper antibiotics use is the leading cause of antimicrobial resistance. Bacterial co-infection in COVID-19 patients is the basis for the use of antibiotics in the management of COVID-19. COVID-19 pandemic has seriously impacted antibiotic stewardship and increased the global usage of antibiotics, worsening the antimicrobial resistance problem. The use of antibiotics among COVID-19 patients is high but there are limited studies in the context of Nepal. This study aimed to find out the prevalence of antibiotic use among hospitalised COVID-19 patients in a tertiary care centre. Methods: A descriptive cross-sectional study was conducted on hospitalised COVID-19 patients from April 2021 to June 2021 in a tertiary care centre. Ethical approval was taken from the Institutional Review Committee (Reference number: 2078/79/05). The hospital data were collected in the proforma by reviewing the patient’s medical records during the study period of 2 months. Convenience sampling was used. Point estimate and 95% Confidence Interval were calculated. Results: Among 106 hospitalised COVID-19 patients, the prevalence of antibiotic use was 104 (98.11%) (95.52-100, 95% Confidence Interval). About 74 (71.15%) of patients received multiple antibiotics. The most common classes of antibiotics used were cephalosporins, seen in 85 (81.73%) and macrolides, seen in 57 (54.81%) patients. Conclusions: The prevalence of antibiotic use among hospitalised COVID-19 patients was found to be higher when compared to other studies conducted in similar settings.en-USAntibioticsBacterial infectionCo-infectionCOVID-19Article